Janux Therapeutics Statistics
Share Statistics
Janux Therapeutics has 59.18M
shares outstanding. The number of shares has increased by 13.99%
in one year.
| Shares Outstanding | 59.18M |
| Shares Change (YoY) | 13.99% |
| Shares Change (QoQ) | 2.26% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,540 |
| FTD / Avg. Volume | 0.26% |
Short Selling Information
The latest short interest is 9.65M, so 16.31% of the outstanding
shares have been sold short.
| Short Interest | 9.65M |
| Short % of Shares Out | 16.31% |
| Short % of Float | 28.9% |
| Short Ratio (days to cover) | 16.68 |
Valuation Ratios
The PE ratio is -41.71 and the forward
PE ratio is -10.88.
Janux Therapeutics's PEG ratio is
13.76.
| PE Ratio | -41.71 |
| Forward PE | -10.88 |
| PS Ratio | 271.8 |
| Forward PS | 3.5 |
| PB Ratio | 2.81 |
| P/FCF Ratio | -65.15 |
| PEG Ratio | 13.76 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Janux Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 59.21,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 59.21 |
| Quick Ratio | 59.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.23 |
| Debt / FCF | -0.52 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $116,351.65 |
| Profits Per Employee | $-758,175.82 |
| Employee Count | 91 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.36% in the
last 52 weeks. The beta is 3.24, so Janux Therapeutics's
price volatility has been higher than the market average.
| Beta | 3.24 |
| 52-Week Price Change | -52.36% |
| 50-Day Moving Average | 29.15 |
| 200-Day Moving Average | 42.47 |
| Relative Strength Index (RSI) | 31.14 |
| Average Volume (20 Days) | 958,573 |
Income Statement
In the last 12 months, Janux Therapeutics had revenue of 10.59M
and earned -68.99M
in profits. Earnings per share was -1.28.
| Revenue | 10.59M |
| Gross Profit | 8.53M |
| Operating Income | -98.85M |
| Net Income | -68.99M |
| EBITDA | -98.85M |
| EBIT | -98.85M |
| Earnings Per Share (EPS) | -1.28 |
Full Income StatementBalance Sheet
The company has 430.61M in cash and 23.02M in
debt, giving a net cash position of 407.58M.
| Cash & Cash Equivalents | 430.61M |
| Total Debt | 23.02M |
| Net Cash | 407.58M |
| Retained Earnings | -237.76M |
| Total Assets | 1.06B |
| Working Capital | 1.02B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -43.81M
and capital expenditures -359K, giving a free cash flow of -44.17M.
| Operating Cash Flow | -43.81M |
| Capital Expenditures | -359K |
| Free Cash Flow | -44.17M |
| FCF Per Share | -0.82 |
Full Cash Flow StatementMargins
Gross margin is 80.54%, with operating and profit margins of -933.58% and -651.62%.
| Gross Margin | 80.54% |
| Operating Margin | -933.58% |
| Pretax Margin | -651.62% |
| Profit Margin | -651.62% |
| EBITDA Margin | -933.58% |
| EBIT Margin | -933.58% |
| FCF Margin | -417.2% |
